Allergic Bronchopulmonary Aspergillosis
AbstractAllergic bronchopulmonary aspergillosis (ABPA), a progressive fungal allergic lung disease, is a common complication of asthma or cystic fibrosis. Although ABPA has been recognized since the 1950s, recent research has underscored the importance of Th2 immune deviation and granulocyte activation in its pathogenesis. There is also strong evidence of widespread under-diagnosis due to the complexity and lack of standardization of diagnostic criteria. Treatment has long focused on downregulation of the inflammatory response with prolonged courses of oral glucocorticosteroids, but more recently concerns with steroid toxicity and availability of new treatment modalities has led to trials of oral azoles, inhaled amphotericin, pulse intravenous steroids, and subcutaneously-injected anti-IgE monoclonal antibody omalizumab, all of which show evidence of efficacy and reduced toxicity. View Full-Text
Share & Cite This Article
Tracy, M.C.; Okorie, C.U.A.; Foley, E.A.; Moss, R.B. Allergic Bronchopulmonary Aspergillosis. J. Fungi 2016, 2, 17.
Tracy MC, Okorie CUA, Foley EA, Moss RB. Allergic Bronchopulmonary Aspergillosis. Journal of Fungi. 2016; 2(2):17.Chicago/Turabian Style
Tracy, Michael C.; Okorie, Caroline U.A.; Foley, Elizabeth A.; Moss, Richard B. 2016. "Allergic Bronchopulmonary Aspergillosis." J. Fungi 2, no. 2: 17.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.